Investigational dopamine antagonists for the treatment of schizophrenia
| Autor: | Chi-Un Pae, Tae Youn Jun, Prakash S. Masand, Soo-Jung Lee, Changsu Han, Ashwin A. Patkar, Sheng Min Wang |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
MEDLINE Cariprazine PsycINFO CINAHL 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine medicine Animals Humans Pharmacology (medical) Psychiatry Brexpiprazole Pharmacology Receptors Dopamine D2 business.industry Dopamine antagonist Drugs Investigational General Medicine BL-1020 030227 psychiatry Clinical trial Dopamine D2 Receptor Antagonists chemistry Drug Design Schizophrenia Dopamine Antagonists business 030217 neurology & neurosurgery Antipsychotic Agents medicine.drug |
| Zdroj: | Expert Opinion on Investigational Drugs. 26:687-698 |
| ISSN: | 1744-7658 1354-3784 |
| Popis: | Schizophrenia is a debilitating illness with a chronic impact on social function and daily living. Although various antipsychotics are available, there are still many challenges and unmet needs. Thus, many compounds with diverse mechanisms have been investigated, but all approved antipsychotics still require interactions with dopamine D2 receptors. Areas covered: We searched for investigational drugs using the key words 'dopamine' and 'schizophrenia' in American and European clinical trial registers (clinicaltrials.gov; clinicaltrialsregister.eu). Published articles were searched in PubMed, Embase, Medline, PsycINFO, Cumulative Index to Nursing and Allied Health Literature (CINAHL), the Web of Science and the Cochrane Central Register of Controlled Trials Library. Expert opinion: The prospect of developing a dopamine antagonist is hopeful. Brexpiprazole and cariprazine, which were agents listed as 'investigational dopamine antagonists,' just received FDA approval. Novel agents such as BL 1020, ITI-007, and JNJ-37822681 have solid published data available, and agents such as L-THP, Lu AF35700, S33138, and SB-773812 are under vigorous investigation. However, the expected benefits of the newly developed antagonists may not be great because they offer little enhanced efficacy for negative symptoms, cognition and functional outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|